Article
Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
Vaccine - 25 Feb 2000
Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H
Abstract excerpt
After primary infection in childhood, varicella zoster virus (VZV) remains latent in the dorsal route ganglia. Its reactivation later in life can lead to a zoster episode. VZV-specific, T-cell-mediated immunity (VZV-CMI) is likely to be important in preventing symptomatic reactivation. As CMI declines with age, a vaccine enhancing VZV-CMI might be effective in decreasing the incidence or severity of zoster in...
Topics
- Aged
- Aging
- Antigens, Viral
- B-Lymphocytes
- Child
- Cytokines
- Dose-Response Relationship, Immunologic
- Double-Blind Method
- Herpes Zoster
- Herpesvirus 3, Human
- Humans
- Lymphocyte Activation
- Middle Aged
- Phenotype